Since /01/2014 Private practice Ophthalmology, Retinal Medical Specialty and AMD, private office

Size: px

Start display at page:

Download "Since /01/2014 Private practice Ophthalmology, Retinal Medical Specialty and AMD, private office"

Marilynn Lambert
6 years ago
Views:

1 Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist SELARL CABINET DOCTEUR GONZALEZ 27, Boulevard des Minimes Toulouse! cabinet.dr.gonzalez@wanadoo.fr Fax : PRESENT PROFESSIONAL POSITION OPHTALMOLOGIST DOCTOR, Private practice Retinal medical Specialist, AMD in particular Installation year : 1988 TRAINING ( ) : General Medical Practice and SPECIALITY 1977 : Human Biology Grade 1987 Medical Doctor Degree THESIS : Macular sub-retinal neovascularisation and its treatment with Krypton laser. General review, computer clinical and angiographical study. Treatment results for the 85 studied cases. CES of OPHTHALMOLOGY, Ophthalmology Medical Specialist Degree PROFESSIONAL EXPERIENCE Since /01/2014 Private practice Ophthalmology, Retinal Medical Specialty and AMD, private office Marked by a dot and underlined, underneath are the medical exams,which I have been the first to introduce in the Region Midi Pyrénées Angiographies : - FA (Fluorescein Angiography), since ICG (Infracyanin Green Angiography), since SPECTRALIS and SPECTRALIS OCT Angiography, since 2007 Until now I have been the only physician in the Midi Pyrénées Region to have a common practice of Spectralis system FA and ICG, retinal and optic nerve Spectral domain OCT. Laser : all types, including multi waves,since 1988 OCT 3 (Optic Confocal Tomography), since 1995 Photodynamic Therapy, since 2000 IVT (Intra-Vitreal Injection),1 er surgical unit in Private office in Midi-Pyrénées, since 2005 (only 10 surgical units like this in France) HIV ophthalmologic Pathology 1

Contactology RESEARCH BACKGROUND Fundamental Research 1989 1991 Professeur Soleihavoup Laboratory ( Histo-Cytology department, Purpan CHU Toulouse) Antikératin antibody profiling of retinal pigment

2 Contactology RESEARCH BACKGROUND Fundamental Research Professeur Soleihavoup Laboratory ( Histo-Cytology department, Purpan CHU Toulouse) Antikératin antibody profiling of retinal pigment epithelium. publication about this work : n 20 reference below Based on the results obtained during this period, I submitted many working hypothesis about ARMD etiopathogenesis, with the specific retinal pigment epithelium role and in particular mitochondrial pigment epithelium dysfunction. Those hypothesis were based on regular scientific literature revue and clinical studies published in an international way by well known teams. At this time, I have established links with other researchers in the course of many meetings. Interest for a coordinated research These contacts referred to above have for a few of them become permanent and I am looking for teams able to cooperate together in order to demonstrate and confirm those hypothesis. I would like to federate several research teams to make them more dynamic and productive. The basic idea is to get them together, taking advantage of their specific competences, cross fertilize between the groups with a common goal which is to better understand AMD pathogenesis and more over retinal pathologies. In this respect, it is a common feature of the pharma industry that research is terribly expensive and that a lot of duplication is going on, at a tremendous cost. I believe that, as it is presently done for ALZHEIMER s disease, where a number of pharma companies are beginning to work on a common project, the same kind of research could be developed for AMD, because it is simply not true that fundamental research is competitive in the economic sense of the word. In particular, findings of toxicity in the research programs should be shared between the companies, which would improve the speed at which innovation can be brought into the sector. This could also be a very interesting topic for a joint funding between the industry and the EU Research and Development Framework Programme. Clinical Research Absolutely aware of the scientific progress importance in medical practice, and always seeking for innovation, I ve been precursor : - In the retinal pathologies investigative techniques use (cf ref n 8,26,28,30,33) - In the therapeutic principles use : PED treatment (cf ref n 15), «Baxter» principle use development for CMV retinitis treatment, of Thalidomide, for SIDA patients (cf ref n 22,27) - In new treatments development : no steroid anti-inflammatory treatments in general and/or subconjunctival administration to treat exudative reactions and complications of ADM, Diabetic retinopathy, retinal vein occlusion (cf ref n 1, 2,3) - In new therapeutic protocol suggestions : retrofoveolar neovascular AMD complication treated with series of 3 IVT (cf ref n 9,10,11,12,4,5,6). Others international medical teams have confirmed this 2

3 protocol, with similar results, much better and promising than those of other standard studies. (cf ARVO 2010 meeting abstracts and conferences) - In having initiative in protocol and therapies : in contrast with usual practice, I recommend not to give Triamcinolone by IVT for the treatment of exudative reaction complicating AMD, Diabetic retinopathy, retinal vein occlusion ( now quite dropped method ) - In my medical practice of Ophthalmology : private practice, no in clinic and/or hospital, with surgical unit in the office SCIENTIFIC AND CLINICAL WORKS (published and /or presented in meetings) Internationals 1 - Diclofenac with photodynamic therapy for choroidal neovascularisation complicating AMD C Gonzales, ARVO 2005 and Mickaelson Meeting Subconjonctival injection of triamcinolone and photodynamic therapy (PDT) for exsudative choroidal neovascularisation (CNV) complicating age macular degeneration (AMD) C Gonzalez, ARVO 2006 et Euretina Subconjonctival injection of triamcinolone for the treatment of macular oedema complicating diabetic retinopathy C Gonzalez, ARVO Intravitreal pegaptanib for retrofoveolar neovascular myopia maculopathy C Gonzalez, ARVO Intravitreal pegaptanib for retrofoveolar neovascularisation complicating age macular degeneration (AMD), with predominant pigment epithelium(pe) atrophic areas C Gonzalez, Euretina Analysis of intravitreal ranibizumab injections effects on exudative reaction complicating subfoveal choroidal neovascular age related macular degeneration (AMD) C Gonzalez, EVER No functional vision improvement after intravitreal ranibizumab injections (IVT) for retrofoveolar choroidal neovascular age related macular degeneration (AMD),why? C Gonzalez, EVER Interest of spectralis HRA + OCT for the follow-up of age macular degeneration (AMD),with and without neovascular complication C Gonzalez, Heidelberg meeting Treatment of retrofoveolar neovascular AMD by series of 3 ranibizumab injections,1 year ½ follow-up 10 - Treatment of retrofoveolar neovascular AMD by 3 injections series of ranibizumab followed by maintenace treatment with 3 pegaptanib IVT after 1 year follow-up 11 - Treatment of retrofoveolar neovascular AMD by series of 3 ranibizumab injections,1 year ½ follow-up 12 - Treatment of retrofoveolar neovascular AMD by 3 injections series of ranibizumab followed by maintenace treatment with 3 pegaptanib IVT after 1 year follow-up 13 - Intravitreal pegaptanib for retrofoveolar neovascular age related macular degeneration, in pseudo vitelliform and/or drusenoid pigment epithelium detachment shape C Gonzalez, SOE Intravitreal ranibizumab for retrofoveolar neovascular age related macular degeneration, in pseudo vitelliform and/or drusenoid pigment epithelium detachment shape C Gonzalez, SOE Treatment of retrofoveolar neovascular AMD by series of 3 ranibizumab injections, 1 year ½ follow-up C Gonzalez, EVER

4 16 - Treatment of focal and/or diffuse central serous chorioretinopathy by series of 3 intravitreal injections of ranibizumab C Gonzalez, EURETINA Treatment of macular retinal telangiectasies type 1 by series of 3 ranibizumab injections after 1 year follow-up C Gonzalez, EURETINA Series of 3 ranibizumab injections, for the treatment of retrofoveolar neovascular age related macular degeneration, 2 ½ years follow-up C Gonzalez, EVRS Treatment of Type 1 idiopathic Macular Telangiectasia by series of 3 Ranibizumab injections after 1 year follow-up C Gonzalez, EVRS Treatment of type 1 idiopathic macular telangiectasia by series of 3 intravitreal injections of ranibizumab C Gonzalez, EVER AMD edemas: diagnosis, follow-up, therapeutic, prognosis, spectral domain oct, angiography, icg interests C Gonzalez, EVER Treatment of focal and/or diffuse central serous chorioretinopathy by series of 3 intravitreal injections of ranibizumab C Gonzalez, EVER Treatment of diabetic retinopathy macular edema by series of 3 ranibizumab injections after 2 years ½ follow-up C Gonzalez, EURETINA Treatment of retinal vein occlusion by series of 3 ranibizumab intravitreal injections C Gonzalez, EURETINA Intravitreal injections of ranibizumab for retrofoveolar neovascular age related macular degeneration, in pseudo vitelliform and/or drusenoid pigment epithelium detachment shape C Gonzalez, EVER Retinal vein occlusion: treatment by series of 3 ranibizumab ivt C Gonzalez, EVER Diabetic retinopathy macular edema: treatment by series of 3 intravitreal ranibizumab injections after 3 years follow-up C Gonzalez, EVER Atrophic areas and neovascular AMD: characteristics, evolution of atrophic lesions, during protocol treatment by series of 3 ranibizumab ivt, 4 years follow-up C Gonzalez, ARVO Neovascular AMD with atrophic areas. characteristics, evolution of atrophic lesions associated to neovascular AMD treated by series of 3 ranibizumab ivt protocol, 4 years follow-up C Gonzalez, EURETINA AMD atrophic areas. characteristics, evolution study, and its interest.3 years follow-up C Gonzalez, EURETINA Atrophic areas and/withneovascular AMD.Characteristics,evolutionof atrophic lesions associatedto neovascular AMD treated by series of 2 ranibizumabivt protocol, 4 years follow-up C Gonzalez, EVER Age macular degeneration-alzheimer disease: relevance and interest of ophthalmologic exam in detection and follow-up of Alzheimer disease C Gonzalez, EVER AMD atrophic areas. Characteristics, evolution study, and its interest. 3 years follow-up C Gonzalez, EVER Ophthalmologic exam in Age Macular Degeneration-Alzheimer Disease:its interest in detection, follow-up of AMD, of Alzheimer disease, its relevance to highlight the links and correlations between AMD and AD C Gonzalez, ARVO Age Macular Degeneration- Alzheimer Disease : Relevance and Interest of OCT, OCT en face exam in detection and in follow-up of AMD and Alzheimer Disease C Gonzalez, EURETINA Age Macular Degeneration- Alzheimer Disease : interest of Ophthalmologic Exam in Detection, Follow-up of AMD, of Alzheimer Disease, its relevance to highlight the Links and Correlations between AMD and AD. C Gonzalez, EURETINA Age Macular Degeneration- Alzheimer Disease In-Between Correlations: One Year Screening, Follow-Up and Outcome 4

5 C Gonzalez, EVER AMD Drusenoid deposits characterization: Interest of OCT, OCT en FACE C Gonzalez, EVER Neovascular AMD with high recurrences and Atrophic Areas: Potential relationship between Neovascular complication and Atrophy C Gonzalez, EVER 2013 Europeans Publications in periodicals with reading committees 40 Retinal serous detachments. Interest of acetazolamide C Gonzalez. J.Fr. Ophtalmol., Study of contrast sensitivity in two groups of patients. Normal and amblyopic. C Gonzalez, C Labro-Leredde, Opthalmologies, Serous Drusen or micro-pigment epithelium detachment. Neovascular risk factor. C Gonzalez, Ophtalmologies, 1999 Communications 43 Subretinal new vessels treated by laser krypton photocoagulation. C Gonzalez, Société de Photocoagulation, Ocular fundus white spots C Gonzalez, Société Méditerranéenne du Midi, Antikeratin antibody profiling of retinal pigment epithelium cells C Gonzalez, Congrès international sur la macula, The high myopia new vessels. C Gonzalez, Congrès d Ophtalmologie, Interest of Thalidomide in the treatment of inflammation occuring with CMV chorioretinitis during VIH infection. C Gonzalez, M Obadia, S Averous, B Marchou, P Massip. Symposium «maladie à CMV au cours de l infection par le VIH», 1997 Nationals Publications in periodicals of specialty 48 The biometry : the iris, the retina : why, how, the ophthalmologist point of vue. C Gonzalez, Convergence, mai number, News, prospects, attitude about age macular degeneration ( AMD ) C Gonzalez, Journal Association Rétina France, february number, New prospects concerning medical retina C Gonzalez, Journal Association Rétina France, december number, 2008 Communication in meetings 51 Pigment epithelium degeneration :angiographic signs without complications C Gonzalez, SFO CMV Retinopathy, «what about Thalidomide?» C Gonzalez, M Obadia, SOIF, Late frame ICG hyperfluorescent pictures in AMD patients. C Gonzalez, SFO, New vessels and inflammation : clinical case report C Gonzalez, SOIE et SOIF, Interest and place of OCT in AMD and its neovascular complication follow-up C Gonzalez, SFO,

6 56 Pegaptanib intravitreal injections (IVT) for the treatment of AMD previously treated by Dynamic Phototherapy ( PDT ). C Gonzalez, SFO, Recurrences features after loading inductive anti-vegf ranibizumab (Lucentis) treatment C Gonzalez, SFO, AMD edemas, spectral domain OCT Interest C Gonzalez, SFO, Treatment of focal and/or diffuse diabetic retinopathy macular edema by series of 3 intravitreal injections of ranibizumab C Gonzalez, SFO, Atrophic areas with Neovascular AMD: atrophic areas study interest, and their evolution, 3 years follow-up C Gonzalez, SFO, Age Macular Degeneration- Alzheimer Disease : interest of Ophthalmologic Exam in Detection, Follow-up of Alzheimer Disease C Gonzalez, SFO, Age Macular Degeneration- Alzheimer Disease : Interest of OCT, OCT en face exam in detection and in follow-up of Alzheimer Disease C Gonzalez, SFO, 2013 Communications in specialist s meetings 63 Dynamic Phototherapy, one year and a half after The treatment and its indications. The follow-up and the re-treatment indications C Gonzalez, Spécialists in Ophtalmology meeting, AMD and therapeutic prospects C Gonzalez, Association Retina France meeting, Occult New vessels PDT interest for the treatment of foveolar subretinal occult neovascularisation C Gonzalez, Novavision, 2003 et Last research marchs for new vessels treatment. PDT interest for the treatment of subretinal occult new vessels C Gonzalez, Spécialists in Ophtalmology meeting, AMD and therapeutic prospects C Gonzalez, Spécialists in Ophtalmology meeting, OCT and AMD C Gonzalez, Spécialists in Ophtalmology meeting, AMD: clinical cases report 70 Angiography meeting 71 AMD : Follow-up, Prospect, Screening, Prévention 72 Angiogenesis: VEGF et anti-vegf (physiology & physiopathology) 73 - Anti- VEGF News C Gonzalez, FMC, IVT unit in private practice and office C Gonzalez, DMLA en pratique, AMD and general practitioner C Gonzalez, FMC 2007 et 2010 ACTIVE MEMBER OF SCIENTIFIC GROUPS AND LEARNED SOCIETIES International AAO 6

7 ARVO EURETINA EVER EVRS SOE SOIE SOIF National SFO 7

Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist

Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist PRESENT PROFESSIONAL POSITION OPHTALMOLOGIST DOCTOR, Private practice Retinal medical Specialist, DMLA in particular Installation year